Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07363980

Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study

The Coronary Computed Tomography Angiography in Rheumatoid Arthritis study is part of the multinational, prospective, observational Autoimmunity and Atherosclerosis in Rheumatic Diseases cohort (https://atacc-rd.com) that includes comprehensive baseline and follow-up assessments at 3, 5, and 10 years. It comprises a main protocol and several optional modules, including a Cardiac Imaging Module, Biobanking Module, Pulmonary Module, and Anxiety and Depression Module.

The study aims to advance understanding of cardiopulmonary and psychological comorbidities in rheumatoid arthritis, to improve early identification and management, and to enhance insights into underlying disease mechanisms-ultimately refining risk stratification and targeted prevention strategies.

The study includes 4,000 patients with rheumatoid arthritis enrolled through the Cardiac Imaging Module in the main protocol. Participants undergo coronary computed tomography angiography, pulmonary function testing, physical examination, questionnaires, and biobanking, supplemented by genetic, proteomic, metabolomic, and microbiome profiling.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

About this study

This prospective, observational study follows individuals with rheumatoid arthritis over time to understand how the disease and its treatment relate to cardiovascular, pulmonary, psychological, and biological outcomes. The study collects standardized clinical data from outpatient rheumatology clinics, complemented by advanced imaging, biological sample collection, and linkage to national health registries.

Study Procedures and Visit Schedule Participants are enrolled during routine or ad-hoc outpatient visits. After informed consent, a baseline evaluation is performed, followed by standardized follow-up visits after approximately 3, 5, and 10 years (± 3-6 months).

At baseline, demographic and lifestyle factors (age, sex, education, smoking, alcohol, physical activity, and family history) are recorded together with anthropometric measures (height, weight, waist circumference) and rheumatoid arthritis characteristics (serologic status, disease duration, erosive disease, and disease activity scores). Concomitant diseases and medications are documented, and vital signs and blood pressure are measured.

Patient-reported outcomes include validated questionnaires on quality of life (Short Form 36, version 1), functional ability (Multidimensional Health Assessment Questionnaire), work productivity (Work Productivity and Activity Impairment - General Health), fatigue and pain visual analogue scales, physical activity (International Physical Activity Questionnaire - Short Form), and shortness of breath (University of California, San Diego Shortness of Breath Questionnaire). Laboratory results, including markers of inflammation and metabolic status, are obtained according to routine standards.

Follow-up visits repeat these assessments to evaluate disease activity, lifestyle changes, and incident comorbidities. Events such as hospitalizations, procedures, and deaths are continuously updated through registry linkage, ensuring complete longitudinal follow-up.

Registry Data Sources All participants are linked to national Danish health and administrative registries to enable comprehensive, long-term follow-up. The study integrates data from the National Patient Registry, the Danish Rheumatology Quality Database, the Civil Registration System, the Danish National Causes of Death Registry, the Western Denmark Heart Registry, the Danish Heart Registry, the Danish Stroke Registry, the Danish National Vascular Registry, the Danish National Database of Reimbursed Prescriptions, the Clinical Laboratory Information System, the Register of Laboratory Results for Research, and the Danish Research Institute for Economic Analysis and Modelling. Linkage across these registries allows continuous capture of clinical events, treatments, and vital status, ensuring complete longitudinal follow-up and verification of outcomes recorded during study visits.

Governance The study is governed by an executive steering committee responsible for overall scientific direction, study design, resource allocation, and regulatory compliance. Supporting boards and advisory groups contribute to patient involvement, methodological quality, and international collaboration. Dedicated centers coordinate site operations, biobanking, cardiac imaging, and data analysis to ensure standardized procedures and data integrity across all participating sites.

All procedures are conducted in accordance with Danish and European data-protection regulations, and data are stored and managed in secure systems compliant with the General Data Protection Regulation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fulfill the ACR/EULAR-2010 criteria for rheumatoid arthritis
  • Attending or has attended at least one visit during the last two years in rheumatology outpatient clinic for diagnostic or monitoring purposes related to rheumatoid arthritis
  • Age 50-75 years

Exclusion criteria

  • Diagnosed with overlapping systemic autoimmune diseases other than secondary Sjogren's syndrome
  • Active cancer
  • Prior coronary atherosclerotic symptoms as defined by myocardial infraction, percutaneous coronary intervention, or coronary artery bypass grafting
  • Allergy to radiocontrast agents
  • Estimated glomerular filtration rate (eGFR) < 30 mL/min
  • BMI > 35 kg/m2
  • Persistent atrial fibrillation

Treatment and study plan

Primary outcomes

  1. Number of participants with a first occurrence of Major Adverse Cardiovascular Events (MACE)

    Time frame: 3, 5 and 10 years

    • Cardiovascular death as defined by death from any of the following causes: Ischemic heart disease; Sudden cardiac death; Ventricular tachycardia; Other cardiac arrhythmias; Heart failure; Fatal ischemic stroke; Sudden undefined death; Unwitnessed or unknown cause of death
    • Hospitalization for non-fatal myocardial infarction, including hospitalization for PCI and CABG
    • Hospitalization for non-fatal ischemic stroke
  2. Number of participants with a first occurrence of any ischemic cardiovascular events, including MACE

    Time frame: 3, 5 and 10 years

    Hospitalization for cerebrovascular disease (transient ischemic attack). Hospitalization for peripheral vascular disease. Hospitalization for peripheral vascular surgery. Cardiovascular death as defined by death from any of the following causes: Ischemic heart disease; Sudden cardiac death; Ventricular tachycardia; Other cardiac arrhythmias; Heart failure; Fatal ischemic stroke; Sudden undefined death; Unwitnessed or unknown cause of death. Hospitalization for non-fatal myocardial infarction, including hospitalization for PCI and CABG. Hospitalization for non-fatal ischemic stroke

  3. Number of participants with all-cause death (all-cause mortality)

    Time frame: 3, 5 and 10 years

    Death from any cause

Secondary outcomes

  1. Coronary Artery Calcium Score (Agatston score)

    Time frame: Baseline

    Coronary Artery Calcium Score (CACS), Agatston units. Minimum: 0. Maximum: No upper limit. Higher score indicates worse outcome (more coronary artery calcification).

  2. The coronary artery plaque surface extent at baseline evaluated for the percent composition of non-calcified-, mixed-, and calcified plaques

    Time frame: Baseline

    Quantitative plaque measurement

  3. Change in Coronary Artery Calcium Score (Agatston units) from baseline to 3 years

    Time frame: Baseline and 3 years

    Coronary Artery Calcium Score (Agatston score), Agatston units. Change (Δ) in Coronary Artery Calcium Score (CACS) calculated as 3-year CACS minus baseline CACS. Minimum: No lower limit (negative). Maximum: No upper limit (positive). A positive change indicates increasing calcification (worse); a negative change indicates decreasing calcification (better).

  4. The quantitative difference in coronary artery plaque surface extent from baseline to 3 years evaluated for the percent composition of non-calcified-, mixed-, and calcified plaques

    Time frame: Baseline and 3 year

    Quantitative plaque measurement

  5. Number of participants with a occurrence of hospitalization for cerebrovascular disease

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  6. Number of participants with a first occurrence of hospitalization for non-fatal myocardial infarction

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  7. Number of participants with a occurrence of hospitalization for non-fatal ischemic stroke

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  8. Number of participants with a occurrence of hospitalization for peripheral vascular disease

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  9. Number of participants with a occurrence of hospitalization for peripheral vascular surgery

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  10. Number of participants with a occurrence of hospitalization for thromboembolic events as defined by deep vein thrombosis and pulmonary embolism

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  11. Number of participants with a first occurrence of hospitalization for PCI

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  12. Number of participants with a first occurrence of hospitalization for CABG

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  13. Number of participants with a first occurrence of treatment for stable angina pectoris

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  14. Number of participants with a occurrence of treatment for atrial fibrillation and flutter

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  15. Number of participants with sudden death

    Time frame: 3, 5 and 10 years

    Source of data: record and registry

  16. Number of participants with cardiovascular death

    Time frame: 3, 5 and 10 years

    Source of data: record and registry

  17. Number of participants with a occurrence of treatment for essential hypertension with/without complications

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  18. Number of participants with a occurrence of treatment for disorders of lipoprotein metabolism and other lipidemias

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  19. Number of participants with a occurrence of treatment for diabetes mellitus

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  20. Number of participants with a occurrence of hospitalization for respiratory disease

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  21. Number of participants with a occurrence of hospitalization or specialist-initiated treatment for interstitial pulmonary diseases

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  22. Number of participants with a occurrence of hospitalization or specialist-initiated treatment for chronic lower respiratory diseases

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  23. Number of participants with a occurrence of hospitalization or specialist-initiated treatment for anxiety disorders, including generalized anxiety disorder

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  24. Number of participants with a occurrence of hospitalization or specialist-initiated treatment for a depressive episode or recurrent major depressive disorder

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  25. Number of participants with a occurrence of general practitioner-initiated treatment for anxiety disorders

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  26. Number of participants with a occurrence of general practitioner-initiated treatment for depression

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  27. Number of participants with a occurrence of referral to a psychologist or psychiatrist

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  28. Number of participants with a occurrence of infection with Mycobacterium tuberculosis

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  29. Number of participants with a occurrence of opportunistic infections

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  30. Number of participants with a occurrence of hospitalization for infections (suspected/confirmed)

    Time frame: 3, 5 and 10 years

    Source of data: patient, record, registry

  31. Proteomics concentrations

    Time frame: Baseline, 3, 5 and 10 years

    Blood sample

  32. Metabolomics concentration

    Time frame: Baseline, 3, 5 and 10 years

    Blood and stool sample

  33. Microbiome profile of stool

    Time frame: Baseline, 3, 5 and 10 years

    Stool sample

  34. Genome-, epigenom-, and RNA sequencing

    Time frame: Baseline, 3, 5 and 10 years

    Blood sample

Sponsors and collaborators

Lead sponsor

Ellen Margrethe Hauge

Other

Collaborators

  • ATACC-RD consortium
  • Aarhus University Hospital
  • Alfasigma S.p.A.
  • Independent Research Fund Denmark
  • The Danish Rheumatism Association
  • University of Aarhus

Registry information

Acronym: COTIRA

Important dates

Study start
2024
Primary completion
2038
Study completion
2040
First posted
Jan 23, 2026
Registry last updated
Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.